Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-02-01
DOI
10.3389/fphar.2019.00039
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s
- (2018) Marie-Theres Binder et al. INFLAMMATORY BOWEL DISEASES
- The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohnʼs Disease Effector T Cells In Vivo
- (2017) Sebastian Zundler et al. INFLAMMATORY BOWEL DISEASES
- Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases
- (2017) Sebastian Zundler et al. INFLAMMATORY BOWEL DISEASES
- Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
- (2017) Friederike Fuchs et al. Frontiers in Immunology
- Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
- (2017) Sebastian Zundler et al. Frontiers in Immunology
- Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
- (2016) Gaik W. Tew et al. GASTROENTEROLOGY
- Leukocyte Trafficking to the Small Intestine and Colon
- (2016) Aida Habtezion et al. GASTROENTEROLOGY
- Blockade of αEβ7 integrin suppresses accumulation of CD8+and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo
- (2016) Sebastian Zundler et al. GUT
- Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease
- (2015) P. Luthra et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease
- (2015) Lianjie Lin et al. MEDICINE
- Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
- (2015) Shi Xu PHARMACEUTICAL RESEARCH
- Review article: anti-adhesion therapies for inflammatory bowel disease
- (2014) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design
- (2014) Bart ECG de Goeij et al. mAbs
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
- (2013) Tim Wyant et al. mAbs
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes
- (2011) EG Stefanich et al. BRITISH JOURNAL OF PHARMACOLOGY
- Inflammatory Bowel Disease
- (2010) Arthur Kaser et al. Annual Review of Immunology
- Engineering therapeutic monoclonal antibodies
- (2008) Xiao-yun Liu et al. IMMUNOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now